Uncategorized - February 11, 2015
Modz Creates Angry Birds™ Themed Meter
Finnish company Modz has designed an Angry Birds™ themed blood glucose meter for children with Type 1 diabetes that gives them points and rewards for testing regularly. With video game qualities, the meter uses different game levels and points to motivate children to remember to test. Regular testing is critical for diabetics to ensure their […]
Acquisition - January 7, 2015
Novo Renews Racing Pact
Novo Nordisk and the Chip Ganassi Racing Teams (CGRT) have inked a multi-year extension of their partnership, renewing Novo Nordisk as the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the Verizon IndyCar Series. Kimball, 29, from Camarillo, California, is the first and only licensed driver with diabetes […]
Uncategorized - December 8, 2014
Virus May Cause Type 1 Diabetes
Researchers have found a virus in the pancreas of patients with type 1 diabetes. The discovery may offer the potential for both treatment and a vaccine. For many years it has been suspected that a virus is a possible cause of type 1 diabetes. A new study has found a virus present in the pancreas […]
Drug Development Pharma - November 24, 2014
CHMP Approves Victoza
The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, a once-daily human glucagon-like peptide-1 (GLP-1) analogue, to […]
Uncategorized - November 7, 2014
Novo Nordisk Launches Insulin Cartridge
This week Novo Nordisk launched NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue specifically designed for insulin pumps, according to the company web site. This new treatment solution, which contains NovoRapid® (insulin aspart) – a rapid-acting insulin from Novo Nordisk – is expected to make insulin pump therapy more convenient for people with diabetes […]
New Market - November 3, 2014
FDA approves AstraZeneca’s XIGDUO
The US Food and Drug Administration has approved AstraZeneca’s once-daily XIGDUO XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. XIGDUO XR is the first and only once-daily combination tablet of an SGLT2 inhibitor and metformin HCl extended-release to be approved in the United States. XIGDUO XR is indicated […]
